Christian Schem
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K, Rachakonda S, Braun M, Huober J, Jank P, Sinn H, Zahm D, Felder B, Hanusch C, Teply-Szymanski J, Marme F, Fehm T, Thomalla J, Sinn B, Stiewe T, Marczyk M, Blohmer J, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover D, Solbach C, Metzger-Filho O, Jackisch C, Geyer C, Fasching P, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. Cell Rep Med 2024; 5:101825.
Nov 19, 2024Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Nov 19, 2024Cell Rep Med 2024; 5:101825
Denkert Carsten, Schneeweiss Andreas, Rey Julia, Karn Thomas, Hattesohl Akira, Weber Karsten E, Rachakonda Sivaramakrishna, Braun Michael, Huober Jens, Jank Paul, Sinn Hans-Peter, Zahm Dirk-Michael, Felder Bärbel, Hanusch Claus, Teply-Szymanski Julia, Marme Frederik, Fehm Tanja N, Thomalla Jörg, Sinn Bruno Valentin, Stiewe Thorsten, Marczyk Michal, Blohmer Jens-Uwe, van Mackelenbergh Marion T, Schem Christian, Staib Peter, Link Theresa, Müller Volkmar, Stickeler Elmar, Stover Daniel G, Solbach Christine, Metzger-Filho Otto, Jackisch Christian, Geyer Charles E, Fasching Peter Andreas, Pusztai Lajos, Nekljudova Valentina, Untch Michael, Loibl Sibylle
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Sinn B, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching P, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res 2024; 26:138.
Sep 24, 2024On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Sep 24, 2024Breast Cancer Res 2024; 26:138
Sinn Bruno Valentin, Sychra Katharina, Untch Michael, Karn Thomas, van Mackelenbergh Marion T, Huober Jens, Schmitt Wolfgang Daniel, Marme Frederik, Schem Christian, Solbach Christine, Stickeler Elmar, Tesch Hans, Fasching Peter Andreas, Schneeweiss Andreas, Müller Volkmar, Holtschmidt Johannes, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. Clin Cancer Res 2024
Jun 5, 2024An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jun 5, 2024Clin Cancer Res 2024
Jank Paul, Karn Thomas, van Mackelenbergh Marion T, Lindner Judith L, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marme Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja N, Schem Christian, Stickeler Elmar, Fasching Peter Andreas, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
Apr 1, 2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Apr 1, 2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
Jan 13, 2020A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Jan 13, 2020Clin Cancer Res 2020; 26:1896-1904
Karn Thomas, Schem Christian, Young Brandon M, Hanusch Claus, Stickeler Elmar, Huober Jens, van Mackelenbergh Marion, Leyland-Jones Brian, Fehm Tanja, Nekljudova Valentina, Untch Michael, Gerber Bernd, Holtrich Uwe, Müller Volkmar, Meissner Tobias, Weber Karsten E, Solbach Christine, Denkert Carsten, Engels Knut, Fasching Peter A, Sinn Bruno V, Schrader Iris, Budczies Jan, Marme Frederik, Loibl Sibylle
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Massa C, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Huober J, Marme F, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer 2020; 8
Jan 1, 2020Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Jan 1, 2020J Immunother Cancer 2020; 8
Massa Chiara, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter A, Untch Michael, Loibl Sibylle, Weber Karsten, Huober Jens, Marme Frederik, Karn Thomas, Denkert Carsten, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion, Thomalla Jörg, Seliger Barbara
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Sinn B, Denkert C, Seliger B, von Minckwitz G, Huober J, Ataseven B, Stickeler E, Schem C, Marme F, Klauschen F, Taube E, Karn T, Blohmer J, Symmans W, Fasching P, Schmitt W, Weber K, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019; 21:142.
Dec 11, 2019Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Dec 11, 2019Breast Cancer Res 2019; 21:142
Sinn Bruno Valentin, Denkert Carsten, Seliger Barbara, von Minckwitz Gunter, Huober Jens, Ataseven Beyhan, Stickeler Elmar, Schem Christian, Marme Frederik, Klauschen Frederick, Taube Eliane Tabea, Karn Thomas, Blohmer Jens-Uwe, Symmans William Fraser, Fasching Peter A, Schmitt Wolfgang Daniel, Weber Karsten E, Loibl Sibylle
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Witzel I, Untch M, Stickeler E, Schem C, Marme F, Mackelenbergh M, Karn T, Huober J, Lück H, Weber K, Denkert C, Fasching P, Wirtz R, Loibl S, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer 2019; 121:1009-1015.
Nov 15, 2019Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Nov 15, 2019Br J Cancer 2019; 121:1009-1015
Witzel Isabell, Untch Michael, Stickeler Elmar, Schem Christian, Marme Frederik, Mackelenbergh Marion von, Karn Thomas, Huober Jens, Lück Hans-Joachim, Weber Karsten, Denkert Carsten, Fasching Peter A, Wirtz Ralph, Loibl Sibylle, Müller Volkmar
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019; 26:3892-3901.
Jul 26, 2019Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Jul 26, 2019Ann Surg Oncol 2019; 26:3892-3901
Krug David, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Schem Christian, Schneeweiss Andreas, Untch Michael, Debus Jürgen, von Minckwitz Gunter, Kühn Thorsten, Hilfrich Jörn, Heil Joerg, Lederer Bianca, Seither Fenja, Nekljudova Valentina, Ataseven Beyhan, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Ditsch Nina, Gerber Bernd, Hanusch Claus, Loibl Sibylle
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019; 37:2226-2234.
May 13, 2019NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
May 13, 2019J Clin Oncol 2019; 37:2226-2234
Untch Michael, Hackmann John, Blohmer Jens-Uwe, Rhiem Kerstin, Schmitt Wolfgang D, Furlanetto Jenny, Gerber Bernd, Huober Jens, Nekljudova Valentina, von Minckwitz Gunter, Hanusch Claus, Just Marianne, Fasching Peter A, Jackisch Christian, Schneeweiss Andreas, Schmatloch Sabine, Aktas Bahriye, Denkert Carsten, Schem Christian, Wiebringhaus Hermann, Kümmel Sherko, Warm Mathias, Loibl Sibylle
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
May 10, 2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
May 10, 2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36:2281-2287.
May 23, 2018BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
May 23, 2018J Clin Oncol 2018; 36:2281-2287
Fasching Peter A, Huober Jens, Liedtke Cornelia, Weinshilboum Richard M, Wang Liewei, Ingle James N, Müller Volkmar, Nekljudova Valentina, Weber Karsten E, Rack Brigitte, Rübner Matthias, von Minckwitz Gunter, Fehm Tanja, Blohmer Jens-Uwe, Costa Serban Dan, Loibl Sibylle, Hu Chunling, Hart Steven N, Shimelis Hermela, Moore Raymond, Schem Christian, Tesch Hans, Untch Michael, Hilfrich Jörn, Rezai Mahdi, Gerber Bernd, Couch Fergus J
Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Loibl S, Kronenwett R, von Minckwitz G, Staebler A, Müller V, Darb-Esfahani S, Hartmann A, Furlanetto J, Kümmel S, Pfitzner B, Engels K, Schem C, Marme F, Krappmann K, Huober J, Weber K, Denkert C. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clin Cancer Res 2018; 24:3358-3365.
Apr 4, 2018Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Apr 4, 2018Clin Cancer Res 2018; 24:3358-3365
Loibl Sibylle, Kronenwett Ralf, von Minckwitz Gunter, Staebler Annette, Müller Volkmar, Darb-Esfahani Silvia, Hartmann Arndt, Furlanetto Jenny, Kümmel Sherko, Pfitzner Berit Maria, Engels Knut, Schem Christian, Marme Frederik, Krappmann Kristin, Huober Jens, Weber Karsten, Denkert Carsten
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol 2018; 36:1308-1316.
Mar 15, 2018Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Mar 15, 2018J Clin Oncol 2018; 36:1308-1316
Untch Michael, Loibl Sibylle, Nekljudova Valentina, Fehm Tanja, Hauschild Maik, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Huober Jens, Hanusch Claus, Eggemann Holm, Tesch Hans, Fasching Peter A, Rezai Mahdi, Schem Christian, Gerber Bernd, von Minckwitz Gunter, GBG and the AGO-B Study Group
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2017; 19:40-50.
Dec 7, 2017Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Dec 7, 2017Lancet Oncol 2017; 19:40-50
Denkert Carsten, Engels Knut, Schneeweiss Andreas, Hartmann Arndt, Noske Aurelia, Fasching Peter A, Jackisch Christian, van Mackelenbergh Marion, Sinn Peter, Schem Christian, Hanusch Claus, Untch Michael, Kümmel Sherko, Pfitzner Berit M, Karn Thomas, von Minckwitz Gunter, Darb-Esfahani Silvia, Lederer Bianca, Heppner Barbara I, Weber Karsten E, Budczies Jan, Huober Jens, Klauschen Frederick, Furlanetto Jenny, Schmitt Wolfgang D, Blohmer Jens-Uwe, Loibl Sibylle
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3:1378-1385.
Oct 1, 2017Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Oct 1, 2017JAMA Oncol 2017; 3:1378-1385
Hahnen Eric, Huober Jens, Rhiem Kerstin, Costa Serban, Altmüller Janine, Hanusch Claus, Thiele Holger, Müller Volkmar, Nürnberg Peter, Karn Thomas, Nekljudova Valentina, Untch Michael, von Minckwitz Gunter, Neidhardt Guido, Schem Christian, Lederer Bianca, Hauke Jan, Loibl Sibylle, Kröber Sandra, Schneeweiss Andreas, Denkert Carsten, Fasching Peter A, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Kümmel Sherko, Schmutzler Rita K
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat 2017; 167:59-71.
Sep 5, 2017Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Sep 5, 2017Breast Cancer Res Treat 2017; 167:59-71
van Mackelenbergh Marion T, Weber Karsten E, von Minckwitz Gunter, Untch Michael, Schneeweiss Andreas, Müller Volkmar, Kümmel Sherko, Blohmer Jens-Uwe, Fasching Peter A, Huober Jens, Hanusch Claus, Jackisch Christian, Stickeler Elmar, Marme Frederik, Schem Christian, Karn Thomas, Nekljudova Valentina, Denkert Carsten, Loibl Sibylle
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer 2017; 84:1-8.
Jul 30, 2017Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Jul 30, 2017Eur J Cancer 2017; 84:1-8
Kümmel Sherko, Burchardi Nicole, von Minckwitz Gunter, Fasching Peter A, Klare Peter, Engels Knut, Denkert Carsten, Schneeweiss Andreas, Jackisch Christian, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Blohmer Jens Uwe, Untch Michael, Schem Christian, Huober Jens, Paepke Stefan, Loibl Sibylle
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 2017; 23:5384-5393.
Jul 5, 2017Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Jul 5, 2017Clin Cancer Res 2017; 23:5384-5393
Riethdorf Sabine, Untch Michael, von Minckwitz Gunter, Schem Christian, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Weber Karsten, Nekljudova Valentina, Loibl Sibylle, Müller Volkmar, Pantel Klaus
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
Jul 6, 2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Jul 6, 2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A